New preclinical results support the anti-fibrotic potential of engineered macrophages in multiple fibrosis models Engineered TIM4-expressing macrophages correct defective efferocytosis in MASH, demonstrating potent anti-fibrotic activity PHILADELPHIA, Nov. 17, 2024 /PRNewswire/ -- Carisma...
Read More Details
Finally We wish PressBee provided you with enough information of ( Carisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of Liver Fibrosis at AASLD The Liver Meeting® 2024 )
Also on site :